公司评级与股价表现 - 摩根士丹利于2025年10月31日将吉利德科学股票评级上调至“增持” 同时将目标股价从143美元提升至147美元 [1] - 当前股价为121.08美元 单日上涨2.64美元 涨幅约2.23% 交易区间为114.02美元至121.91美元 [3] - 过去52周股价波动显著 最高点为124.61美元 最低点为86.08美元 [3] 公司产品与行业认可 - 公司产品Yeztugo®（lenacapavir）荣获2025年美国盖伦奖最佳制药产品奖 彰显其在HIV治疗领域的贡献 [2] - Yeztugo®是一款重大创新药物 作为一年两次注射的HIV-1衣壳抑制剂 为有HIV-1感染风险的个体提供有效的暴露前预防 [2] 公司市值与交易情况 - 公司当前市值约为1502.4亿美元 在生物制药行业地位显著 [4] - 当日交易量为3,555,932股 显示出投资者的积极参与 [4]

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.GILD is in positive territory. Get the complete picture hereThe U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45 billion.Product sales decreased 2% to $7.3 billion, primarily driven by lower Veklury (remdesivir) and Cell Therapy sales, partially offset by higher HIV and Livdelzi (seladelpar) sales."With multiple potential product launches in 2026, the ...

EARNINGS PREVIEW: Palantir, Robinhood Among Leaders Set To ReportGilead stock reversed its losses early Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot.Yeztugo is a twice-annual injection that aims to prevent HIV infection from taking hold in at-risk people. During the third quarter, it generated $39 million in sales, RBC Capital Markets analyst Brian Abrahams said in a report. He acknowledged that while sales beat sell-side expectations for $35 million, the buy-si ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Gilead Sciences (GILD) came out with quarterly earnings of $2.47 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +14.88%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.95 per share when it actually produced earnings of $2.01, delivering a surprise of +3.08%.Over the last four ...

Gilead Sciences (NasdaqGS:GILD) Q3 2025 Earnings Call October 30, 2025 04:30 PM ET Speaker0Good afternoon, everyone, and welcome to Gilead's Third Quarter twenty twenty five Earnings Conference Call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared remarks followed by our Q and A session. Now I'll hand the call over to Jackie Ross, Senior Vice President of Treasury and Investor Relations.Speaker1Thank you, Rebecca. Just after market closed today, we issued a press release ...

Q325 Financial Results 1 0 D e c e m b e r 2 0 2 4 O c t o b e r 3 0 , 2 0 2 5 Forward-Looking Statements Statements included in this document that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's abili ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for its new prevention drug Yeztugo, helping to boost its profit above Wall Stree... ...

Foster City, CA, October 30, 2025 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations. "We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing uptake of Biktarvy, Descovy and Livdelzi, and positive data for Trodelvy in 1L metastatic triple negative breast cancer," said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. "With multiple potential product launches in 2026, the strongest clinical pipeline in G ...

Key Takeaways Gilead will report Q3 2025 results on Oct. 30, with sales and EPS estimates of $7.46B and $2.15.HIV portfolio strength from Biktarvy, Descovy, and new approval Yeztugo is driving top-line growth.Cell Therapy sales likely declined amid competition, while Trodelvy and Livdelzi demand stayed strong.Biotech bigwig Gilead Sciences, Inc. (GILD)   is scheduled to report third-quarter 2025 results on Oct. 30, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $7.46 bi ...